Serious adverse events · people admitted to intensive care units
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinically important upper GI bleeding · people admitted to intensive care units
H2 receptor antagonists probably leads to lower clinically important upper GI bleeding compared with placebo or no prophylaxis (moderate certainty).
1 finding from 1 review
Nosocomial pneumonia · people admitted to intensive care units
H2 receptor antagonists showed no clear difference in nosocomial pneumonia compared with placebo or no prophylaxis (low certainty).
1 finding from 1 review
ICU mortality · people admitted to intensive care units
H2 receptor antagonists showed no clear difference in all‐cause mortality in ICU compared with placebo or no prophylaxis (low certainty).
1 finding from 1 review
Global symptoms of dyspepsia · adults with functional dyspepsia
Proton pump inhibitors (PPI) showed no clear difference in global symptoms of dyspepsia compared with H2 receptor antagonists (H2RA) (low certainty).
1 finding from 1 review
Quality of life · adults with functional dyspepsia
1 finding from 1 review
Adverse events · adults with functional dyspepsia
Proton pump inhibitors (PPI) showed no clear difference in adverse events compared with H2 receptor antagonists (H2RA) (moderate certainty).
1 finding from 1 review
Intervention not reported
PPI versus placebo Symptomatic outcome measures · patients with heartburn remission in gastro‐oesophageal reflux disease‐like symptoms
The intervention leads to lower PPI versus placebo Symptomatic outcome measures (high certainty).
1 finding from 1 review
Intervention not reported
H2RA versus placebo · patients with heartburn remission in gastro‐oesophageal reflux disease‐like symptoms
The intervention probably leads to lower H2RA versus placebo (moderate certainty).
1 finding from 1 review
Intervention not reported
Prokinetic versus placebo · patients with heartburn remission in gastro‐oesophageal reflux disease‐like symptoms
1 finding from 1 review
Intervention not reported
PPI versus H2RA · patients with heartburn remission in gastro‐oesophageal reflux disease‐like symptoms
The intervention probably leads to lower PPI versus H2RA (moderate certainty).
1 finding from 1 review
Intervention not reported
PPI versus prokinetic · patients with heartburn remission in gastro‐oesophageal reflux disease‐like symptoms
The intervention may leads to lower PPI versus prokinetic (low certainty).
1 finding from 1 review
Intervention not reported
PPI versus placebo · patients with heartburn remission in endoscopy negative reflux disease
The intervention probably leads to lower PPI versus placebo (moderate certainty).
1 finding from 1 review
Intervention not reported
H2RA versus placebo · patients with heartburn remission in endoscopy negative reflux disease
The intervention probably leads to lower H2RA versus placebo (moderate certainty).
1 finding from 1 review
Intervention not reported
PPI versus H2RA · patients with heartburn remission in endoscopy negative reflux disease
The intervention may leads to lower PPI versus H2RA (low certainty).
1 finding from 1 review
Intervention not reported
PPI versus prokinetic · patients with heartburn remission in endoscopy negative reflux disease
The intervention may leads to lower PPI versus prokinetic (low certainty).
1 finding from 1 review